Deng Fuxue, Xia Yong, Fu Michael, Hu Yunfeng, Jia Fang, Rahardjo Yeffry, Duan Yingyi, He Linjing, Chang Jing
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 404100, P.R. China.
Heart & Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH 43210, USA.
Exp Ther Med. 2016 Jun;11(6):2127-2138. doi: 10.3892/etm.2016.3211. Epub 2016 Mar 31.
The impact of heart failure (HF) on acute myocardial infarction (AMI) in patients from southwestern China remains unclear. The present study aimed to compare in-hospital cardiovascular events, mortality and clinical therapies in AMI patients with or without HF in southwestern China. In total, 591 patients with AMI hospitalized between February 2009 and December 2012 were examined; those with a history of HF were excluded. The patients were divided into four groups according to AMI type (ST-elevated or non-ST-elevated AMI) and the presence of HF during hospitalization. Clinical characteristics, in-hospital cardiovascular events, mortality, coronary angiography and treatment were compared. Clinical therapies, specifically evidence-based drug use were analyzed in patients with HF during hospitalization, including angiotensin converting enzyme inhibitors (ACEIs) and β-blockers (BBs). AMI patients with HF had a higher frequency of co-morbidities, lower left ventricular ejection fraction, longer length of hospital stay and a greater risk of in-hospital mortality compared with AMI patients without HF. AMI patients with HF were less likely to be examined by cardiac angiography or treated with reperfusion therapy or recommended medications. AMI patients with HF co-treated with ACEIs and BBs had a significantly higher survival rate (94.4 vs. 67.5%; P<0.001) compared with untreated patients or patients treated with either ACEIs or BBs alone. Logistic regression analysis revealed that HF and cardiogenic shock in patients with AMI were the strongest predictors of in-hospital mortality. AMI patients with HF were at a higher risk of adverse outcomes. Cardiac angiography and timely standard recommended medications were associated with improved clinical outcomes.
在中国西南部地区,心力衰竭(HF)对急性心肌梗死(AMI)患者的影响尚不清楚。本研究旨在比较中国西南部地区伴或不伴HF的AMI患者的院内心血管事件、死亡率及临床治疗情况。共检查了2009年2月至2012年12月期间住院的591例AMI患者;排除有HF病史的患者。根据AMI类型(ST段抬高型或非ST段抬高型AMI)及住院期间是否存在HF将患者分为四组。比较了临床特征、院内心血管事件、死亡率、冠状动脉造影及治疗情况。对住院期间有HF的患者的临床治疗,特别是循证用药进行了分析,包括血管紧张素转换酶抑制剂(ACEIs)和β受体阻滞剂(BBs)。与无HF的AMI患者相比,有HF的AMI患者合并症发生率更高、左心室射血分数更低、住院时间更长且院内死亡风险更大。有HF的AMI患者接受心脏血管造影检查、再灌注治疗或推荐药物治疗的可能性较小。与未治疗患者或仅接受ACEIs或BBs治疗的患者相比,联合使用ACEIs和BBs治疗的有HF的AMI患者生存率显著更高(94.4%对67.5%;P<0.001)。Logistic回归分析显示,AMI患者中的HF和心源性休克是院内死亡的最强预测因素。有HF的AMI患者不良结局风险更高。心脏血管造影检查及及时使用标准推荐药物与改善临床结局相关。